Recent reports have indicated that a new, more dangerous variant of Mpox, formerly known as monkeypox, is on the brink of spreading to the UK. Identified as the clade 1b strain, this variant has already been confirmed in countries like Sweden and Pakistan, following its initial detection in the Democratic Republic of the Congo (DRC). With the World Health Organization declaring it a global health emergency, the situation is becoming increasingly concerning. The disease has rapidly spread to 13 African countries, resulting in over 15,600 reported cases and 537 deaths.
Infectious diseases expert Professor Paul Hunter has warned that it is “very likely” that the new Mpox variant is already present in the UK. While the confirmation of its presence may take a few weeks, as individuals with symptoms need to seek medical attention and undergo testing, the risk remains imminent. Prof Hunter highlighted the fact that the disease initially presents with non-specific symptoms, often resembling flu or COVID, before progressing to the development of characteristic blisters.
Mpox primarily spreads through the exchange of fluids from these lesions, particularly during sexual contact. Despite the severity of the new variant, Prof Hunter reassured that for the majority of individuals, Mpox is a relatively mild illness that resolves on its own. The risk of infection remains low, especially for those not engaged in specific high-risk activities. The DRC strain of Mpox was initially observed among sex workers, indicating the importance of practicing safe sexual behaviors.
The UK Health Security Agency (UKHSA) has stated that the current risk level is considered low, with the existing Mpox vaccine deemed effective against the new clade 1b strain. While a previous Mpox variant, clade 2, prompted a WHO health alert in 2022 and is still circulating in the UK, the new variant poses a potentially greater threat. However, Prof Hunter emphasized that with proper supportive care, the mortality rate of the new variant could be significantly lower if it spreads to Europe.
Individuals exhibiting symptoms that could indicate a Mpox infection are urged to promptly seek medical attention. Whether visiting a genito-urinary clinic or consulting a GP, early detection and treatment are crucial in containing the spread of the disease. Prof Hunter emphasized the importance of providing quality supportive care to reduce mortality rates and enable individuals to recover effectively.
The looming threat of the new deadlier Mpox variant in the UK warrants heightened vigilance and proactive measures to prevent its further spread. With the support of healthcare professionals and the public’s cooperation in adhering to preventive guidelines, the impact of this potentially deadly disease can be mitigated.